ID   VAMP2_HUMAN             Reviewed;         116 AA.
AC   P63027; P19065; Q9BUC2;
DT   31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   09-FEB-2010, sequence version 3.
DT   07-APR-2021, entry version 162.
DE   RecName: Full=Vesicle-associated membrane protein 2 {ECO:0000305};
DE            Short=VAMP-2;
DE   AltName: Full=Synaptobrevin-2;
GN   Name=VAMP2 {ECO:0000312|HGNC:HGNC:12643}; Synonyms=SYB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1976629;
RA   Archer B.T. III, Oezcelik T., Jahn R., Francke U., Suedhof T.C.;
RT   "Structures and chromosomal localizations of two human genes encoding
RT   synaptobrevins 1 and 2.";
RL   J. Biol. Chem. 265:17267-17273(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Peripheral blood;
RA   Nabokina S.M., Lazo P.A., Mollinedo F.;
RT   "Expression of VAMP genes in human neutrophils.";
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RA   Taruscio D., Zoraqi K.G., Falbo V.;
RT   "Genomic structure of human SYB2 gene.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Neuroblastoma, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=8760387; DOI=10.1042/bj3170945;
RA   Jagadish M.N., Fernandez C.S., Hewish D.R., Macaulay S.L., Gough K.H.,
RA   Grusovin J., Verkuylen A., Cosgrove L., Alafaci A., Frenkel M.J.,
RA   Ward C.W.;
RT   "Insulin-responsive tissues contain the core complex protein SNAP-25
RT   (synaptosomal-associated protein 25) A and B isoforms in addition to
RT   syntaxin 4 and synaptobrevins 1 and 2.";
RL   Biochem. J. 317:945-954(1996).
RN   [8]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION) BY C.BOTULINUM NEUROTOXIN TYPE B
RP   AND BY C.TETANI TETANUS TOXIN.
RX   PubMed=7803399; DOI=10.1021/bi00255a017;
RA   Foran P., Shone C.C., Dolly J.O.;
RT   "Differences in the protease activities of tetanus and botulinum B toxins
RT   revealed by the cleavage of vesicle-associated membrane protein and various
RT   sized fragments.";
RL   Biochemistry 33:15365-15374(1994).
RN   [9]
RP   TOPOLOGY.
RX   PubMed=7835332; DOI=10.1002/j.1460-2075.1995.tb06994.x;
RA   Kutay U., Ahnert-Hilger G., Hartmann E., Wiedenmann B., Rapoport T.A.;
RT   "Transport route for synaptobrevin via a novel pathway of insertion into
RT   the endoplasmic reticulum membrane.";
RL   EMBO J. 14:217-223(1995).
RN   [10]
RP   INTERACTION WITH WDFY2; PRKCZ AND PRKCI, COMPLEX FORMATION WITH WDFY2 AND
RP   PRKCZ, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND MUTAGENESIS OF SER-28;
RP   SER-61; SER-75 AND SER-80.
RX   PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x;
RA   Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.;
RT   "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase
RT   Czeta.";
RL   FEBS J. 274:1552-1566(2007).
RN   [11]
RP   RETRACTED PAPER.
RX   PubMed=10932255; DOI=10.1038/77997;
RA   Hanson M.A., Stevens R.C.;
RT   "Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type
RT   B at 2.0 A resolution.";
RL   Nat. Struct. Biol. 7:687-692(2000).
RN   [12]
RP   RETRACTION NOTICE OF PUBMED:10932255.
RX   PubMed=19578378; DOI=10.1038/nsmb0709-795;
RA   Hanson M.A., Stevens R.C.;
RT   "Retraction: Cocrystal structure of synaptobrevin-II bound to botulinum
RT   neurotoxin type B at 2.0 A resolution.";
RL   Nat. Struct. Mol. Biol. 16:795-795(2009).
RN   [13]
RP   INTERACTION WITH ALPHA-SYNUCLEIN/SNCA.
RX   PubMed=20798282; DOI=10.1126/science.1195227;
RA   Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Suedhof T.C.;
RT   "Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.";
RL   Science 329:1663-1667(2010).
RN   [14]
RP   INTERACTION WITH PICALM.
RX   PubMed=22118466; DOI=10.1016/j.cell.2011.10.038;
RA   Miller S.E., Sahlender D.A., Graham S.C., Honing S., Robinson M.S.,
RA   Peden A.A., Owen D.J.;
RT   "The molecular basis for the endocytosis of small R-SNAREs by the clathrin
RT   adaptor CALM.";
RL   Cell 147:1118-1131(2011).
RN   [15]
RP   INTERACTION WITH PICALM.
RX   PubMed=21808019; DOI=10.1073/pnas.1107067108;
RA   Koo S.J., Markovic S., Puchkov D., Mahrenholz C.C., Beceren-Braun F.,
RA   Maritzen T., Dernedde J., Volkmer R., Oschkinat H., Haucke V.;
RT   "SNARE motif-mediated sorting of synaptobrevin by the endocytic adaptors
RT   clathrin assembly lymphoid myeloid leukemia (CALM) and AP180 at synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:13540-13545(2011).
RN   [16]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION) BY C.BOTULINUM NEUROTOXIN TYPES
RP   B; D AND F.
RX   PubMed=22289120; DOI=10.1111/j.1348-0421.2012.00434.x;
RA   Yamamoto H., Ida T., Tsutsuki H., Mori M., Matsumoto T., Kohda T.,
RA   Mukamoto M., Goshima N., Kozaki S., Ihara H.;
RT   "Specificity of botulinum protease for human VAMP family proteins.";
RL   Microbiol. Immunol. 56:245-253(2012).
RN   [17] {ECO:0007744|PDB:3FIE, ECO:0007744|PDB:3FII}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 25-57 IN COMPLEX WITH C.BOTULINUM
RP   NEUROTOXIN F LIGHT CHAIN, PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION) BY
RP   C.BOTULINUM NEUROTOXIN TYPE X, AND MUTAGENESIS OF GLU-41; VAL-50; VAL-53
RP   AND 53-VAL-LEU-54.
RX   PubMed=19543288; DOI=10.1038/nsmb.1626;
RA   Agarwal R., Schmidt J.J., Stafford R.G., Swaminathan S.;
RT   "Mode of VAMP substrate recognition and inhibition of Clostridium botulinum
RT   neurotoxin F.";
RL   Nat. Struct. Mol. Biol. 16:789-794(2009).
RN   [18]
RP   VARIANTS NEDHAHM VAL-43 DEL; ILE-45 DEL; PRO-75; SER-77 AND ALA-78,
RP   CHARACTERIZATION OF VARIANTS NEDHAHM PRO-75 AND ALA-78, AND FUNCTION.
RX   PubMed=30929742; DOI=10.1016/j.ajhg.2019.02.016;
RG   Deciphering Developmental Disorders Study;
RG   SYNAPS Study Group;
RA   Salpietro V., Malintan N.T., Llano-Rivas I., Spaeth C.G., Efthymiou S.,
RA   Striano P., Vandrovcova J., Cutrupi M.C., Chimenz R., David E., Di Rosa G.,
RA   Marce-Grau A., Raspall-Chaure M., Martin-Hernandez E., Zara F., Minetti C.,
RA   Bello O.D., De Zorzi R., Fortuna S., Dauber A., Alkhawaja M., Sultan T.,
RA   Mankad K., Vitobello A., Thomas Q., Mau-Them F.T., Faivre L.,
RA   Martinez-Azorin F., Prada C.E., Macaya A., Kullmann D.M., Rothman J.E.,
RA   Krishnakumar S.S., Houlden H.;
RT   "Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane
RT   Fusion and Impair Human Neurodevelopment.";
RL   Am. J. Hum. Genet. 104:721-730(2019).
CC   -!- FUNCTION: Involved in the targeting and/or fusion of transport vesicles
CC       to their target membrane (By similarity). Major SNARE protein of
CC       synaptic vesicles which mediates fusion of synaptic vesicles to release
CC       neurotransmitters. Essential for fast vesicular exocytosis and
CC       activity-dependent neurotransmitter release as well as fast endocytosis
CC       that mediates rapid reuse of synaptic vesicles (By similarity)
CC       (PubMed:30929742). Modulates the gating characteristics of the delayed
CC       rectifier voltage-dependent potassium channel KCNB1.
CC       {ECO:0000250|UniProtKB:P63044, ECO:0000250|UniProtKB:P63045,
CC       ECO:0000269|PubMed:30929742}.
CC   -!- SUBUNIT: Part of the SNARE core complex containing SNAP25, VAMP2 and
CC       STX1A. This complex binds to CPLX1. Interacts with BVES and STX4 (By
CC       similarity). Interacts with VAPA and VAPB. Interacts with WDFY2, PRKCZ
CC       and PRKCI (PubMed:17313651). Forms a complex with WDFY2 and PRKCZ
CC       (PubMed:17313651). Interacts (via N-terminus) with KCNB1 (via N-
CC       terminus and C-terminus); stimulates the channel inactivation rate of
CC       KCNB1 (By similarity). Interacts with SEPT8; the interaction inhibits
CC       interaction of VAMP2 with SYP. Interacts with SYP; the interaction is
CC       inhibited by interaction with SEPT8 (By similarity). Interacts with
CC       PICALM (PubMed:22118466, PubMed:21808019). Interacts with alpha-
CC       synuclein/SNCA (PubMed:20798282). Interacts with STX3 (By similarity).
CC       {ECO:0000250|UniProtKB:P63044, ECO:0000250|UniProtKB:P63045,
CC       ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:20798282,
CC       ECO:0000269|PubMed:21808019, ECO:0000269|PubMed:22118466}.
CC   -!- INTERACTION:
CC       P63027; Q13520: AQP6; NbExp=3; IntAct=EBI-520113, EBI-13059134;
CC       P63027; Q3SXY8: ARL13B; NbExp=3; IntAct=EBI-520113, EBI-11343438;
CC       P63027; Q9HA82: CERS4; NbExp=3; IntAct=EBI-520113, EBI-2622997;
CC       P63027; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-520113, EBI-6942903;
CC       P63027; Q15125: EBP; NbExp=3; IntAct=EBI-520113, EBI-3915253;
CC       P63027; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-520113, EBI-781551;
CC       P63027; P31937: HIBADH; NbExp=3; IntAct=EBI-520113, EBI-11427100;
CC       P63027; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-520113, EBI-18053395;
CC       P63027; Q8N5M9: JAGN1; NbExp=3; IntAct=EBI-520113, EBI-10266796;
CC       P63027; Q8N6L0: KASH5; NbExp=3; IntAct=EBI-520113, EBI-749265;
CC       P63027; Q5T0T0: MARCHF8; NbExp=3; IntAct=EBI-520113, EBI-14061946;
CC       P63027; O94806: PRKD3; NbExp=7; IntAct=EBI-520113, EBI-1255366;
CC       P63027; Q9NY72: SCN3B; NbExp=3; IntAct=EBI-520113, EBI-17247926;
CC       P63027; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-520113, EBI-10262251;
CC       P63027; Q8TBB6: SLC7A14; NbExp=3; IntAct=EBI-520113, EBI-5235586;
CC       P63027; O95721: SNAP29; NbExp=3; IntAct=EBI-520113, EBI-490676;
CC       P63027; P37840: SNCA; NbExp=5; IntAct=EBI-520113, EBI-985879;
CC       P63027; Q16623: STX1A; NbExp=5; IntAct=EBI-520113, EBI-712466;
CC       P63027; P61266: STX1B; NbExp=3; IntAct=EBI-520113, EBI-9071709;
CC       P63027; P32856-2: STX2; NbExp=3; IntAct=EBI-520113, EBI-11956649;
CC       P63027; Q12846: STX4; NbExp=6; IntAct=EBI-520113, EBI-744942;
CC       P63027; Q96IK0: TMEM101; NbExp=3; IntAct=EBI-520113, EBI-3922699;
CC       P63027; Q8N661: TMEM86B; NbExp=3; IntAct=EBI-520113, EBI-2548832;
CC       P63027; P55072: VCP; NbExp=3; IntAct=EBI-520113, EBI-355164;
CC       P63027; Q3ZAQ7: VMA21; NbExp=3; IntAct=EBI-520113, EBI-1055364;
CC       P63027; D2KHQ9: bont; Xeno; NbExp=2; IntAct=EBI-520113, EBI-7604762;
CC       P63027; A7GBG3: F; Xeno; NbExp=2; IntAct=EBI-520113, EBI-7604673;
CC       P63027; Q57236: F; Xeno; NbExp=3; IntAct=EBI-520113, EBI-15790260;
CC       P63027; O55012: Picalm; Xeno; NbExp=2; IntAct=EBI-520113, EBI-915601;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle, synaptic
CC       vesicle membrane {ECO:0000269|PubMed:17313651}; Single-pass type IV
CC       membrane protein {ECO:0000255}. Cell membrane
CC       {ECO:0000250|UniProtKB:P63045}. Note=Colocalizes with PRKCZ and WDFY2
CC       in intracellular vesicles (PubMed:17313651).
CC       {ECO:0000269|PubMed:17313651}.
CC   -!- TISSUE SPECIFICITY: Nervous system and skeletal muscle.
CC       {ECO:0000269|PubMed:8760387}.
CC   -!- PTM: Phosphorylated by PRKCZ in vitro and this phosphorylation is
CC       increased in the presence of WDFY2. {ECO:0000269|PubMed:17313651}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type B (BoNT/B, botB) which hydrolyzes the 76-Gln-|-Phe-77
CC       bond and probably inhibits neurotransmitter release (PubMed:7803399).
CC       {ECO:0000269|PubMed:7803399, ECO:0000305|PubMed:22289120}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type D (BoNT/D, botD) which probably hydrolyzes the 59-
CC       Lys-|-Leu-60 bond and inhibits neurotransmitter release
CC       (PubMed:22289120). Note that humans are not known to be infected by
CC       C.botulinum type D. {ECO:0000269|PubMed:22289120, ECO:0000305,
CC       ECO:0000305|PubMed:22289120}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type F (BoNT/F, botF) which hydrolyzes the 58-Gln-|-Lys-59
CC       bond and probably inhibits neurotransmitter release (PubMed:19543288).
CC       {ECO:0000305|PubMed:19543288, ECO:0000305|PubMed:22289120}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.tetani tetanus
CC       toxin (tetX) which hydrolyzes the 76-Gln-|-Phe-77 bond and probably
CC       inhibits neurotransmitter release (PubMed:7803399).
CC       {ECO:0000269|PubMed:7803399}.
CC   -!- DISEASE: Neurodevelopmental disorder with hypotonia and autistic
CC       features with or without hyperkinetic movements (NEDHAHM) [MIM:618760]:
CC       An autosomal dominant disorder characterized by axial hypotonia
CC       apparent at birth, global developmental delay, intellectual disability,
CC       seizures, and autistic features. Involuntary hyperkinetic movements are
CC       present in some patients. {ECO:0000269|PubMed:30929742}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the synaptobrevin family. {ECO:0000305}.
CC   -!- CAUTION: A structure of a fragment of this protein in complex with the
CC       catalytic domain of C.botulinum neurotoxin type B (BoNT/B, botB) was
CC       reported; because of the lack of clear and continuous electron density
CC       for the VAMP2 peptide in the complex structure, the paper was retracted
CC       (PubMed:10932255, PubMed:19578378). However this protein is a substrate
CC       for BoNT/B (PubMed:7803399, PubMed:22289120).
CC       {ECO:0000269|PubMed:10932255, ECO:0000269|PubMed:19578378,
CC       ECO:0000269|PubMed:7803399, ECO:0000305|PubMed:22289120}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M36205; AAA60604.1; -; Genomic_DNA.
DR   EMBL; M36201; AAA60604.1; JOINED; Genomic_DNA.
DR   EMBL; M36202; AAA60604.1; JOINED; Genomic_DNA.
DR   EMBL; M36203; AAA60604.1; JOINED; Genomic_DNA.
DR   EMBL; M36204; AAA60604.1; JOINED; Genomic_DNA.
DR   EMBL; AJ225044; CAA12385.1; -; mRNA.
DR   EMBL; AF135372; AAF15551.1; -; Genomic_DNA.
DR   EMBL; AK289555; BAF82244.1; -; mRNA.
DR   EMBL; CH471108; EAW90087.1; -; Genomic_DNA.
DR   EMBL; BC002737; AAH02737.3; -; mRNA.
DR   EMBL; BC019608; AAH19608.1; -; mRNA.
DR   EMBL; BC033870; AAH33870.1; -; mRNA.
DR   CCDS; CCDS32561.1; -.
DR   PIR; B38315; B38315.
DR   RefSeq; NP_055047.2; NM_014232.2.
DR   PDB; 3FIE; X-ray; 2.10 A; C/D=25-57.
DR   PDB; 3FII; X-ray; 2.17 A; B=32-57.
DR   PDB; 3RK2; X-ray; 2.20 A; A/E=28-60.
DR   PDB; 3RK3; X-ray; 3.50 A; A=28-60.
DR   PDB; 3RL0; X-ray; 3.80 A; A/E/I/M/Q/U/Y/c=28-60.
DR   PDBsum; 3FIE; -.
DR   PDBsum; 3FII; -.
DR   PDBsum; 3RK2; -.
DR   PDBsum; 3RK3; -.
DR   PDBsum; 3RL0; -.
DR   BMRB; P63027; -.
DR   SMR; P63027; -.
DR   BioGRID; 112711; 111.
DR   CORUM; P63027; -.
DR   DIP; DIP-39072N; -.
DR   IntAct; P63027; 52.
DR   MINT; P63027; -.
DR   STRING; 9606.ENSP00000314214; -.
DR   ChEMBL; CHEMBL2364160; -.
DR   DrugBank; DB00042; Botulinum Toxin Type B.
DR   TCDB; 1.F.1.1.1; the synaptosomal vesicle fusion pore (svf-pore) family.
DR   iPTMnet; P63027; -.
DR   MetOSite; P63027; -.
DR   PhosphoSitePlus; P63027; -.
DR   SwissPalm; P63027; -.
DR   BioMuta; VAMP2; -.
DR   DMDM; 288558837; -.
DR   EPD; P63027; -.
DR   jPOST; P63027; -.
DR   MassIVE; P63027; -.
DR   MaxQB; P63027; -.
DR   PaxDb; P63027; -.
DR   PeptideAtlas; P63027; -.
DR   PRIDE; P63027; -.
DR   ProteomicsDB; 57471; -.
DR   TopDownProteomics; P63027; -.
DR   Antibodypedia; 24568; 285 antibodies.
DR   DNASU; 6844; -.
DR   Ensembl; ENST00000316509; ENSP00000314214; ENSG00000220205.
DR   GeneID; 6844; -.
DR   KEGG; hsa:6844; -.
DR   UCSC; uc010cnt.2; human.
DR   CTD; 6844; -.
DR   DisGeNET; 6844; -.
DR   GeneCards; VAMP2; -.
DR   HGNC; HGNC:12643; VAMP2.
DR   HPA; ENSG00000220205; Tissue enhanced (brain).
DR   MalaCards; VAMP2; -.
DR   MIM; 185881; gene.
DR   MIM; 618760; phenotype.
DR   neXtProt; NX_P63027; -.
DR   OpenTargets; ENSG00000220205; -.
DR   PharmGKB; PA37267; -.
DR   VEuPathDB; HostDB:ENSG00000220205.8; -.
DR   eggNOG; KOG0860; Eukaryota.
DR   GeneTree; ENSGT00940000158370; -.
DR   InParanoid; P63027; -.
DR   PhylomeDB; P63027; -.
DR   TreeFam; TF313666; -.
DR   PathwayCommons; P63027; -.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-181429; Serotonin Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-199992; trans-Golgi Network Vesicle Budding.
DR   Reactome; R-HSA-210500; Glutamate Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-212676; Dopamine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-264642; Acetylcholine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-264876; Insulin processing.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-5250955; Toxicity of botulinum toxin type D (botD).
DR   Reactome; R-HSA-5250958; Toxicity of botulinum toxin type B (botB).
DR   Reactome; R-HSA-5250981; Toxicity of botulinum toxin type F (botF).
DR   Reactome; R-HSA-5250982; Toxicity of tetanus toxin (tetX).
DR   Reactome; R-HSA-5250989; Toxicity of botulinum toxin type G (botG).
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-888590; GABA synthesis, release, reuptake and degradation.
DR   Reactome; R-HSA-9609523; Insertion of tail-anchored proteins into the endoplasmic reticulum membrane.
DR   BioGRID-ORCS; 6844; 6 hits in 983 CRISPR screens.
DR   ChiTaRS; VAMP2; human.
DR   EvolutionaryTrace; P63027; -.
DR   GeneWiki; VAMP2; -.
DR   GenomeRNAi; 6844; -.
DR   Pharos; P63027; Tbio.
DR   PRO; PR:P63027; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P63027; protein.
DR   Bgee; ENSG00000220205; Expressed in right frontal lobe and 241 other tissues.
DR   ExpressionAtlas; P63027; baseline and differential.
DR   Genevisible; P63027; HS.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB.
DR   GO; GO:0061202; C:clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0060203; C:clathrin-sculpted glutamate transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070083; C:clathrin-sculpted monoamine transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0044306; C:neuron projection terminus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030141; C:secretory granule; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0031201; C:SNARE complex; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0008021; C:synaptic vesicle; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030672; C:synaptic vesicle membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070044; C:synaptobrevin 2-SNAP-25-syntaxin-1a complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070032; C:synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070033; C:synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005802; C:trans-Golgi network; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0042589; C:zymogen granule membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048306; F:calcium-dependent protein binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005516; F:calmodulin binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005543; F:phospholipid binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043621; F:protein self-association; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005484; F:SNAP receptor activity; IBA:GO_Central.
DR   GO; GO:0000149; F:SNARE binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0019905; F:syntaxin binding; IPI:UniProtKB.
DR   GO; GO:0017075; F:syntaxin-1 binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0017156; P:calcium-ion regulated exocytosis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043308; P:eosinophil degranulation; IMP:UniProtKB.
DR   GO; GO:0006887; P:exocytosis; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0043001; P:Golgi to plasma membrane protein transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0061025; P:membrane fusion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0007269; P:neurotransmitter secretion; TAS:Reactome.
DR   GO; GO:0006836; P:neurotransmitter transport; TAS:Reactome.
DR   GO; GO:0090316; P:positive regulation of intracellular protein transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006892; P:post-Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0045048; P:protein insertion into ER membrane; TAS:Reactome.
DR   GO; GO:0015031; P:protein transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0065003; P:protein-containing complex assembly; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1902259; P:regulation of delayed rectifier potassium channel activity; ISS:UniProtKB.
DR   GO; GO:0017157; P:regulation of exocytosis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0009749; P:response to glucose; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0035493; P:SNARE complex assembly; IBA:GO_Central.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; ISS:UniProtKB.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006906; P:vesicle fusion; IMP:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; ISS:ParkinsonsUK-UCL.
DR   DisProt; DP00069; -.
DR   InterPro; IPR001388; Synaptobrevin.
DR   InterPro; IPR016444; Synaptobrevin/VAMP.
DR   InterPro; IPR042855; V_SNARE_CC.
DR   InterPro; IPR028717; VAMP2.
DR   PANTHER; PTHR45701; PTHR45701; 1.
DR   PANTHER; PTHR45701:SF5; PTHR45701:SF5; 1.
DR   Pfam; PF00957; Synaptobrevin; 1.
DR   PIRSF; PIRSF005409; Synaptobrevin_euk; 1.
DR   PRINTS; PR00219; SYNAPTOBREVN.
DR   PROSITE; PS00417; SYNAPTOBREVIN; 1.
DR   PROSITE; PS50892; V_SNARE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell junction; Cell membrane; Coiled coil;
KW   Cytoplasmic vesicle; Disease variant; Membrane; Mental retardation;
KW   Phosphoprotein; Reference proteome; Synapse; Transmembrane;
KW   Transmembrane helix.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P63026"
FT   CHAIN           2..116
FT                   /note="Vesicle-associated membrane protein 2"
FT                   /id="PRO_0000206723"
FT   TOPO_DOM        2..94
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        95..114
FT                   /note="Helical; Anchor for type IV membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        115..116
FT                   /note="Vesicular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          31..91
FT                   /note="v-SNARE coiled-coil homology"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00290"
FT   REGION          92..116
FT                   /note="Required for interaction with SEPT8"
FT                   /evidence="ECO:0000250|UniProtKB:P63045"
FT   SITE            58..59
FT                   /note="(Microbial infection) Cleavage; by C.botulinum
FT                   neurotoxin type F (BoNT/F, botF)"
FT                   /evidence="ECO:0000305|PubMed:19543288"
FT   SITE            76..77
FT                   /note="(Microbial infection) Cleavage; by C.botulinum
FT                   neurotoxin type D (BoNT/D, botD)"
FT                   /evidence="ECO:0000269|PubMed:7803399"
FT   SITE            76..77
FT                   /note="(Microbial infection) Cleavage; by C.tetani toxin
FT                   (tetX)"
FT                   /evidence="ECO:0000269|PubMed:7803399"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63026"
FT   VARIANT         43
FT                   /note="Missing (in NEDHAHM)"
FT                   /evidence="ECO:0000269|PubMed:30929742"
FT                   /id="VAR_083584"
FT   VARIANT         45
FT                   /note="Missing (in NEDHAHM)"
FT                   /evidence="ECO:0000269|PubMed:30929742"
FT                   /id="VAR_083585"
FT   VARIANT         75
FT                   /note="S -> P (in NEDHAHM; impaired vesicle fusion)"
FT                   /evidence="ECO:0000269|PubMed:30929742"
FT                   /id="VAR_083586"
FT   VARIANT         77
FT                   /note="F -> S (in NEDHAHM)"
FT                   /evidence="ECO:0000269|PubMed:30929742"
FT                   /id="VAR_083587"
FT   VARIANT         78
FT                   /note="E -> A (in NEDHAHM; no effect on vesicle fusion)"
FT                   /evidence="ECO:0000269|PubMed:30929742"
FT                   /id="VAR_083588"
FT   MUTAGEN         28
FT                   /note="S->A: Significant loss of phosphorylation; when
FT                   associated with A-61, A-75 and A-80."
FT                   /evidence="ECO:0000269|PubMed:17313651"
FT   MUTAGEN         41
FT                   /note="E->A: 70% reduction in cleavage by C.botulinum
FT                   neurotoxin type F (BoNT/F, botF)."
FT                   /evidence="ECO:0000269|PubMed:19543288"
FT   MUTAGEN         50
FT                   /note="V->D: 65% reduction in cleavage by BoNT/F."
FT                   /evidence="ECO:0000269|PubMed:19543288"
FT   MUTAGEN         53..54
FT                   /note="VL->DD: 98% reduction in cleavage by BoNT/F."
FT                   /evidence="ECO:0000269|PubMed:19543288"
FT   MUTAGEN         53
FT                   /note="V->A: Wild-type cleavage by BoNT/F."
FT                   /evidence="ECO:0000269|PubMed:19543288"
FT   MUTAGEN         53
FT                   /note="V->D: 90% reduction in cleavage by BoNT/F."
FT                   /evidence="ECO:0000269|PubMed:19543288"
FT   MUTAGEN         61
FT                   /note="S->A: Significant loss of phosphorylation; when
FT                   associated with A-28, A-75 and A-80."
FT                   /evidence="ECO:0000269|PubMed:17313651"
FT   MUTAGEN         75
FT                   /note="S->A: Significant loss of phosphorylation; when
FT                   associated with A-28, A-61 and A-80."
FT                   /evidence="ECO:0000269|PubMed:17313651"
FT   MUTAGEN         80
FT                   /note="S->A: Significant loss of phosphorylation; when
FT                   associated with A-28, A-61 and A-75."
FT                   /evidence="ECO:0000269|PubMed:17313651"
FT   CONFLICT        116
FT                   /note="T -> S (in Ref. 1; AAA60604, 2; CAA12385 and 3;
FT                   AAF15551)"
FT                   /evidence="ECO:0000305"
FT   STRAND          34..36
FT                   /evidence="ECO:0007744|PDB:3FIE"
FT   TURN            47..49
FT                   /evidence="ECO:0007744|PDB:3FIE"
FT   HELIX           50..53
FT                   /evidence="ECO:0007744|PDB:3FIE"
SQ   SEQUENCE   116 AA;  12663 MW;  9CD679C4F6F1B5A8 CRC64;
     MSATAATAPP AAPAGEGGPP APPPNLTSNR RLQQTQAQVD EVVDIMRVNV DKVLERDQKL
     SELDDRADAL QAGASQFETS AAKLKRKYWW KNLKMMIILG VICAIILIII IVYFST
//
